Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429807 | 0.89 | MTNR1A (0.58) | ALDH1A1MAPK1HPGDTSHRLMNA | |
| SCHEMBL10148377 | 0.87 | SMN1; SMN2 (0.57) | ALDH1A1MTNR1AMTNR1BBRD4SMN1; SMN2 | |
| SCHEMBL654145 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPK1HPGDTSHRLMNA | |
| SCHEMBL431767 | 0.80 | ALDH1A1 (0.45) | ALDH1A1MAPK1HPGDTSHRLMNA | |
| SCHEMBL8562434 | 0.79 | TDP1 (0.57) | ALDH1A1MAPK1HPGDTSHRMTNR1A | |
| SCHEMBL8562438 | 0.79 | TDP1 (0.57) | ALDH1A1MAPK1HPGDTSHRMTNR1A | |
| SCHEMBL8562432 | 0.79 | TDP1 (0.57) | ALDH1A1MAPK1HPGDTSHRMTNR1A | |
| SCHEMBL31581789 | 0.77 | ALDH1A1 (0.54) | ALDH1A1MAPK1HPGDTSHRLMNA | |
| SCHEMBL5129678 | 0.77 | KMT2A (0.47) | ALDH1A1MAPK1HPGDTSHRKMT2A | |
| SCHEMBL10148387 | 0.76 | MTNR1A (0.42) | ALDH1A1LMNAMTNR1AMTNR1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | ALDH1A1 3577/4885MAPK1 1461/4885HPGD 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.